Phase 1
Pfizer Inc. has dosed its first patient in a Phase Ib clinical trial of PF-06939926 for Duchenne muscular dystrophy (DMD). At the moment, the only approved drug is Sarepta Therapeutics’ Exondys 51 (eteplirsen).
One month after three patients who developed adverse reactions following injections of an unauthorized herpes vaccine filed a lawsuit against Rational Vaccines, the U.S. Food and Drug Administration has launched a criminal investigation into the matter.
Cellectis has found some sure financial footing that will support its efforts through the remainder of the year. The company secured $163.7 million in an initial public offering to develop CART-T products.
Danish pharma giant Novo Nordisk tied up a sickle cell and beta-thalassemia program in a $400 million deal with Ohio-based EpiDestiny.
A company focused on aging-related ailments is looking to infuse new life into its coffers through an initial public offering. Unity Biotechnology is seeking to raise $85 million in the IPO as it takes its lead candidate into the clinic later this year.
Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
Vivaldi Biosciences announced that its chief scientific officer is delivering a presentation today at the World Vaccine Congress. A new nonclinical trial shows that deltaFLU protected against both distantly drifted and shifted influenza strains, as compared to leading licensed flu vaccines.
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
Pfizer, based in New York City, and Allogene Therapeutics, based in South San Francisco, entered into an asset contribution deal, as well as a $300 million Series A round.
Synlogic, based in Cambridge, Massachusetts, announced it had dosed its first patient in its Phase Ib/IIa clinical trial of SYNB1020 for hyperammonemia.
PRESS RELEASES